23:04 , Dec 20, 2018 |  BC Innovations  |  Finance

Third Rock keeps its options open

Third Rock Ventures is cementing its strategy to create newcos that can succeed as stand-alone companies. The VC has ditched the build-to-buy model in favor of one that gives a pharma broad options to multiple...
22:24 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc....
23:08 , Aug 10, 2018 |  BioCentury  |  Finance

Takeda gets Ambys-tious

After a two-year search, Takeda Pharmaceutical Co. Ltd.’s equity investment and option deal with newco Ambys Medicines finally gets the ball rolling on the pharma’s goal of building a liver franchise within its core area...
11:02 , Aug 8, 2018 |  BC Extra  |  Financial News

Ambys launches with $140M from series A, Takeda deal

Liver disease company Ambys Medicines (Redwood City, Calif.) launched on Wednesday with $140 million in funding from a series A round and an option partnership with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Ambys' $60 million series...